Home > Boards > US Listed > Biotechs > MediciNova, Inc. (MNOV)

One view, technical for the most part.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Minding Member Profile
 
Followed By 15
Posts 830
Boards Moderated 0
Alias Born 03/03/10
160x600 placeholder
MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS GlobeNewswire Inc. - 7/11/2019 7:00:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/21/2019 12:13:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:07:04 PM
MediciNova to Present at the JMP Securities Life Sciences Conference GlobeNewswire Inc. - 6/12/2019 7:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:15:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:05:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:03:53 PM
MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS GlobeNewswire Inc. - 6/5/2019 7:00:00 PM
MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference GlobeNewswire Inc. - 5/15/2019 7:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 4:42:49 PM
MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the ... GlobeNewswire Inc. - 5/7/2019 7:00:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/1/2019 5:29:15 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 5:10:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/26/2019 6:22:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 4:33:49 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/25/2019 4:20:32 PM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlobeNewswire Inc. - 4/23/2019 7:00:00 PM
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS GlobeNewswire Inc. - 4/15/2019 7:00:00 PM
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholes... GlobeNewswire Inc. - 4/3/2019 7:00:00 PM
MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire Inc. - 4/1/2019 7:00:00 PM
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multi... GlobeNewswire Inc. - 3/24/2019 7:00:00 PM
MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan GlobeNewswire Inc. - 3/5/2019 6:51:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2019 6:12:08 AM
MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientif... GlobeNewswire Inc. - 2/28/2019 6:00:00 PM
Minding   Thursday, 10/22/15 08:06:00 AM
Re: None
Post # of 392 
One view, technical for the most part.

Kind regards,
Minding

---------------

From http://www.financialmagazin.com/what-will-happen-to-medicinova-inc-next-the-stock-just-reaches-52-week-low/

What Will Happen to MediciNova, Inc. Next? The Stock Just Reaches 52-Week Low

The stock of MediciNova, Inc. (MNOV) hit a new 52-week low and has $2.05 target or 28.00% below today’s $2.85 share price. The 8 months bearish chart indicates high risk for the $84.89 million company. The 1-year low was reported on Oct, 21 by Barchart.com. If the $2.05 price target is reached, the company will be worth $23.77M less.

The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock is up 2.15% or $0.06 after the news, hitting $2.85 per share. About 107,871 shares traded hands or 41.33% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 18.42% since March 18, 2015 and is downtrending. It has underperformed by 15.15% the S&P500.

Analysts await MediciNova, Inc. (NASDAQ:MNOV) to reports earnings on October, 29. After $-0.09 actual EPS reported by MediciNova, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

According to Zacks, “MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.”

The institutional sentiment increased to 1 in Q2 2015. Its up 0.55, from 0.45 in 2015Q1. The ratio increased, as 5 funds sold all MediciNova, Inc. shares owned while 4 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 2.52 million shares or 0.18% more from 2.51 million shares in 2015Q1.

Essex Woodlands Health Ventures Inc. holds 0.83% of its portfolio in MediciNova, Inc. for 1.17 million shares. Bridgeway Capital Management Inc owns 66,592 shares or 0.01% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 3,020 shares. The United Kingdom-based Barclays Plc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 60,997 shares.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist